Tucson Clinical Research Institute
Not reportedTucson, Arizona, 85712, United States
Site contacts (1)
Girish KaramchandaniPrincipal investigator
CLINICAL STUDY · NCT07881458
A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Not yet recruitingPhase 3Interventional
Sponsored by Eli Lilly and Company
- Condition
- Obesity, Overweight, Diabetes Mellitus, Type 2
- Study locations
- 75 reported sites
- Study updated
- 19 Oct 2026
- Source
- ClinicalTrials.gov
Overall study status is shown above. Individual hospitals may have a different recruitment status.
THE STUDY
About this study
The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared to tirzepatide for body weight reduction in participants with obesity or overweight and type 2 diabetes.
Participation in the study will last about 2 years.
Participation in the study will last about 2 years.
Full official title
A Phase 3 Study to Investigate the Efficacy and Safety of LY900043 in Adult Participants With Obesity or Overweight and Type 2 Diabetes
PARTICIPATION
Who may participate
- Minimum age
- 18 Years
- Maximum age
- Not reported
- Sex eligibility
- All sexes
- Healthy volunteers
- Not accepted
Only the study team can confirm eligibility. The registry criteria below are not a medical recommendation.
Full inclusion and exclusion criteria
Inclusion Criteria:
* Have type 2 diabetes
* Have a stable self-reported body weight (\<5% body weight change) for 90 days prior to screening
* Have a BMI of ≥27 kg/m2 at screening
* Have a history of at least 1 self-reported unsuccessful dietary effort to reduce body weight
Exclusion Criteria:
* Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening)
* Have a prior or planned endoscopic procedure and/or device-based therapy for obesity and/or type 2 diabetes (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
* Have type 1 diabetes
* Have taken any of the following within 90 days prior to screening
* medications with direct amylin, glucagon-like peptide-1 (GLP-1) or glucagon-dependent insulinotropic polypeptide (GIP) receptor activity, including compounded therapies
* dipeptidyl peptidase 4 (DPP-4) inhibitors, and
* insulin
* Have had within 90 days prior to screening:
* heart attack
* stroke
* coronary artery revascularization
* unstable angina, or
* hospitalization due to congestive heart failure
* Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure
* Have taken medications or alternative remedies intended for weight loss within 90 days of screening
* Have type 2 diabetes
* Have a stable self-reported body weight (\<5% body weight change) for 90 days prior to screening
* Have a BMI of ≥27 kg/m2 at screening
* Have a history of at least 1 self-reported unsuccessful dietary effort to reduce body weight
Exclusion Criteria:
* Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening)
* Have a prior or planned endoscopic procedure and/or device-based therapy for obesity and/or type 2 diabetes (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
* Have type 1 diabetes
* Have taken any of the following within 90 days prior to screening
* medications with direct amylin, glucagon-like peptide-1 (GLP-1) or glucagon-dependent insulinotropic polypeptide (GIP) receptor activity, including compounded therapies
* dipeptidyl peptidase 4 (DPP-4) inhibitors, and
* insulin
* Have had within 90 days prior to screening:
* heart attack
* stroke
* coronary artery revascularization
* unstable angina, or
* hospitalization due to congestive heart failure
* Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure
* Have taken medications or alternative remedies intended for weight loss within 90 days of screening
NEAR YOU
Study locations worldwide
75 sitesCheck the individual site’s status and contact the listed study team for current availability.
75 sites shown
Pacific Clinical Studies Inc.
Not reportedLos Alamitos, California, 90720, United States
Site contacts (2)
Name not reportedContactPhone: 562-598-0600 ext 205
Etsegenet AyelePrincipal investigator
Los Angeles Institute for Metabolic Research
Not reportedLos Angeles, California, 90015, United States
University of Colorado Anschutz Medical Campus
Not reportedAurora, Colorado, 80045, United States
American Research Centers of Florida
Not reportedPembroke Pines, Florida, 33027, United States
Encore Medical Research - Weston
Not reportedWeston, Florida, 33331, United States
Care Access - Dalton - Clinical Trials Center by Walmart & Care Access
Not reportedDalton, Georgia, 30720, United States
Site contacts (2)
Name not reportedContactPhone: 877-791-0656
Chukwukanene OfiaeliPrincipal investigator
Pacific Diabetes & Endocrine Center
Not reportedHonolulu, Hawaii, 96817, United States
DM Clinical Research - Indianapolis
Not reportedIndianapolis, Indiana, 46254, United States
Care Access - Eunice
Not reportedEunice, Louisiana, 70535, United States
Tandem Clinical Research
Not reportedMarrero, Louisiana, 70072, United States
Care Access - St. Louis
Not reportedSt Louis, Missouri, 63131, United States
Site contacts (1)
Anthony MargheritaPrincipal investigator
IMA Clinical Research Warren
Not reportedWarren Township, New Jersey, 07059, United States
Site contacts (1)
Samar HameedPrincipal investigator
NYC Research
Not reportedNew York, New York, 10016, United States
Site contacts (2)
Name not reportedContactPhone: 516-574-9232
Anastasios ManessisPrincipal investigator
IMA Clinical Research NYC Midtown
Not reportedNew York, New York, 10036, United States
Site contacts (1)
Eli ShalenbergPrincipal investigator
IMA Clinical Research Austin
Not reportedAustin, Texas, 78745, United States
Diabetes and Thyroid Center of Ft. Worth
Not reportedFort Worth, Texas, 76132, United States
Juno Research
Not reportedHouston, Texas, 77040, United States
Care Access - Houston - Clinical Trials Center by Walmart & Care Access
Not reportedHouston, Texas, 77082, United States
ERA Health Research-Texas
Not reportedMidland, Texas, 79707, United States
Texas Valley Clinical Research (TVCR) - Mission
Not reportedMission, Texas, 78572, United States
Site contacts (1)
Alejandro Gonzalez CamposPrincipal investigator
IMA Clinical Research San Antonio
Not reportedSan Antonio, Texas, 78229, United States
Care Access - Tyler - Clinical Trials Center by Walmart & Care Access
Not reportedTyler, Texas, 75704, United States
Washington Center for Weight Management and Research
Not reportedArlington, Virginia, 22206, United States
Eastside Research Associates
Not reportedRedmond, Washington, 98052, United States
Site contacts (2)
Name not reportedContactPhone: (425) 869-6828
Christopher PricePrincipal investigator
Centro de Pesquisa Sao Lucas
Not reportedCampinas, 13060-803, Brazil
Site contacts (2)
Name not reportedContactPhone: 55 19 3343-8688
Danilo Villagelin NetoPrincipal investigator
Cline Research Center
Not reportedCuritiba, 80030-480, Brazil
Núcleo de Pesquisa Clínica do Rio Grande do Sul
Not reportedPorto Alegre, 90430-001, Brazil
Site contacts (2)
Name not reportedContactPhone: 555137796400
Luis Henrique CananiPrincipal investigator
IBPClin - Instituto Brasil de Pesquisa Clínica
Not reportedRio de Janeiro, 20241-180, Brazil
Site contacts (2)
Name not reportedContactPhone: 552125277979
Renata Alexandra PinheiroPrincipal investigator
CPCLIN
Not reportedSão Paulo, 01228-200, Brazil
CEPIC - Centro Paulista de Investigação Clínica
Not reportedSão Paulo, 04266-010, Brazil
Site contacts (2)
Name not reportedContactPhone: 551122713450
Breno Balabem AlvesPrincipal investigator
The Second Hospital of Jilin University
Not reportedChangchun, 130041, China
Site contacts (1)
Hanqing CaiPrincipal investigator
Jinan Central Hospital
Not reportedJinan, 250013, China
Site contacts (1)
Nianrong MiPrincipal investigator
The First Affiliated Hospital of Henan University of Science &Technology
Not reportedLuoyang Shi, 471023, China
The Second Affiliated Hospital of Nanjing Medical University
Not reportedNanjing, 210011, China
Ningbo First Hospital
Not reportedNingbo, 315010, China
The First Hospital of Hebei Medical University
Not reportedShijiazhuang, 50000, China
Site contacts (1)
Huijuan MaPrincipal investigator
Tianjin Medical University Zhu Xianyi Memorial Hospital
Not reportedTianjin, 300400, China
Site contacts (1)
Liming ChenPrincipal investigator
StudyPoint Duisburg
Not reportedDuisburg, 47269, Germany
Site contacts (2)
Name not reportedContactPhone: +491725448897
Matthias KuensterPrincipal investigator
Diabetes Zentrum Wilhelmsburg
Not reportedHamburg, 21109, Germany
Institut für Diabetesforschung GmbH Münster
Not reportedMünster, 48145, Germany
Schwerpunktpraxis für Diabetes und Ernährungsmedizin Dr. med. Winfried Keuthage
Not reportedMünster, 48153, Germany
FutureMeds Offenbach
Not reportedOffenbach, 63065, Germany
Site contacts (2)
Name not reportedContactPhone: 0049 69 247433849
Christel ContzenPrincipal investigator
RED-Institut GmbH
Not reportedOldenburg, 23758, Germany
Medical Corporation Chiseikai Tokyo Center Clinic
Not reportedChūōku, 103-0027, Japan
Tokyo Asbo Clinic
Not reportedChūōku, 104-0031, Japan
Chiba Saiseikai Narashino hospital
Not reportedNarashino, 275-8580, Japan
Soka Sugiura Internal Medicine Clinic
Not reportedSōka, 340-0015, Japan
Tsuchiura Beryl Clinic
Not reportedTsuchiura, 300-0062, Japan
Latin Clinical Trial Center
Not reportedSan Juan, 00909, Puerto Rico
Site contacts (2)
Name not reportedContactPhone: 7879859911
Alex Gonzalez-BossoloPrincipal investigator
CMI Cardiologie - Dr. Mercea Corina Delia
Not reportedBaia Mare, 430124, Romania
C.M.D.T.A. Neomed
Not reportedBrasov, 500283, Romania
Geea Medical Easy Diet
Not reportedBucharest, 010627, Romania
Centrul Medical NutriLife
Not reportedBucharest, 013764, Romania
Futuremeds - București
Not reportedBucharest, 031441, Romania
Site contacts (2)
Name not reportedContactPhone: +40 723 680 497
Oana-Andreea ParliteanuPrincipal investigator
Futuremeds - Craiova 2
Not reportedCraiova, 200528, Romania
Site contacts (2)
Name not reportedContactPhone: 40763670811
Ionela Mihaela VladuPrincipal investigator
Futuremeds - Galați
Not reportedGalați, 800183, Romania
Site contacts (2)
Name not reportedContactPhone: 0040724405355
Cristina-Victoria MistodiePrincipal investigator
Gama Diamed
Not reportedMangalia, 905500, Romania
Site contacts (2)
Name not reportedContactPhone: 0040241740581
Amalia Thury-BurileanuPrincipal investigator
Diabdana
Not reportedOradea, 410147, Romania
Clinica Korall
Not reportedSatu Mare, 440055, Romania
Korea University Ansan Hospital
Not reportedAnsan-si, 15355, South Korea
Chosun University Hospital
Not reportedGwangju, 61453, South Korea
Site contacts (1)
Sang Yong KimPrincipal investigator
Seoul National University Bundang Hospital
Not reportedSeongnam, 13620, South Korea
Site contacts (1)
Soo LimPrincipal investigator
Nowon Eulji Medical Center, Eulji University
Not reportedSeoul, 01830, South Korea
Severance Hospital, Yonsei University Health System
Not reportedSeoul, 03722, South Korea
Site contacts (1)
Byung Wan LeePrincipal investigator
CHUAC-Complejo Hospitalario Universitario A Coruña
Not reportedA Coruña, 15006, Spain
Site contacts (2)
Name not reportedContactPhone: 655624017
Alfonso Soto GonzalezPrincipal investigator
Hospital Universitario de La Ribera
Not reportedAlzira, 46600, Spain
Hospital Universitari Vall d'Hebron
Not reportedBarcelona, 08035, Spain
Hospital Clínic de Barcelona
Not reportedBarcelona, 08036, Spain
Complejo Hospitalario Universitario de Ferrol (CHUF)- Hospital Naval
Not reportedFerrol, 15405, Spain
Site contacts (1)
Alma Maria Prieto tenreiroPrincipal investigator
Hospital Vithas La Salud
Not reportedGranada, 18008, Spain
Site contacts (2)
Name not reportedContactPhone: 658011529
Cristobal Morales PortilloPrincipal investigator
H.R.U Málaga - Hospital Civil
Not reportedMálaga, 29009, Spain
Hospital Universitario Virgen Del Rocio
Not reportedSeville, 41013, Spain
Vithas Hospital Sevilla
Not reportedSeville, 41950, Spain
Site contacts (2)
Name not reportedContactPhone: 658011529
Cristobal Morales PortilloPrincipal investigator
Hsinchu Mackay Memorial Hospital
Not reportedHsinchu, 300, Taiwan
Site contacts (1)
Lawrence LiuPrincipal investigator
No centres match this search. Try another hospital, city, state or country.
WHAT IS BEING STUDIED
Treatments and study groups
Interventions
eloralintide and tirzepatide
Administered SC
Study groups: EloraTZP
Other names: LY900043
Tirzepatide
Administered SC
Study groups: Tirzepatide
Other names: LY3298176
Study groups
EloraTZP
Participants will receive EloraTZP subcutaneously (SC)
Interventions: Drug: eloralintide and tirzepatide
Tirzepatide
Participants will receive tirzepatide SC
Interventions: Drug: Tirzepatide
RESEARCH DETAILS
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomized
- Study model
- Parallel
- Masking
- Double
- Enrolment
- 1,000 participants · Estimated
- Who is masked
- Participant, Investigator
TIMELINE & MEASURES
Dates and outcomes
- Study started
- Nov 2026 · Estimated
- Primary completion
- Oct 2029 · Estimated
- Study completion
- Nov 2029 · Estimated
- First registered
- 19 Oct 2026 · Actual
- Last registry update
- 19 Oct 2026 · Actual
- Status last verified
- Oct 2026
Primary outcomes (1)
Percent Change from Baseline in Body Weight
Not reported.
Time frame: Baseline, Week 100
Secondary outcomes (21)
Change from Baseline in Waist Circumference
Not reported.
Time frame: Baseline, Week 100
Change from Baseline in Hemoglobin A1c (HbA1c)
Not reported.
Time frame: Baseline, Week 100
Change from Baseline in Systolic Blood Pressure
Not reported.
Time frame: Baseline, Week 100
Percent Change from Baseline in High-Sensitivity C-Reactive Protein (hsCRP)
Not reported.
Time frame: Baseline, Week 100
Percent Change from Baseline in Total Body Fat Mass
Not reported.
Time frame: Baseline, Week 100
Change from Baseline in Body Mass Index (BMI)
Not reported.
Time frame: Baseline, Week 100
Change from Baseline in Fasting Glucose
Not reported.
Time frame: Baseline, Week 100
Percentage of Participants who Achieve a Composite of Body Weight Reduction ≥ 15% and HbA1c <6.5%
Not reported.
Time frame: Week 100
Percent Change from Baseline in Total Cholesterol
Not reported.
Time frame: Baseline, Week 100
Percent Change from Baseline in Fasting Insulin
Not reported.
Time frame: Baseline, Week 100
Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)
Not reported.
Time frame: Baseline, Week 100
Change from Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite CT) Total Score
Not reported.
Time frame: Baseline, Week 100
Change from Baseline in EQ-5D-5L Score
Not reported.
Time frame: Baseline, Week 100
Change from Baseline in Eating Behaviors and Attitudes Questionnaire (EBAQ) Score
Not reported.
Time frame: Baseline, Week 100
Achievement of Improved Categorical Shift in Patient Global Impression of Severity (PGIS) Physical Function Weight
Not reported.
Time frame: Baseline, Week 100
Percentage of Participants with a Change in Medication Use
Not reported.
Time frame: Baseline, Week 100
Overall Functional Assessment of Chronic Illness Therapy, Item GP5 (FACT-GP5) Score
Not reported.
Time frame: Week 100
Pharmacokinetics (PK): Maximum Concentration of Eloralintide at Steady State (Cmax,ss)
Not reported.
Time frame: Baseline through Week 100
PK: Area Under the Concentration Versus Time Curve of Eloralintide for One Dosing Interval at Steady State (AUC(0-ᴛ)ss)
Not reported.
Time frame: Baseline through Week 100
PK: Maximum Concentration of Tirzepatide at Steady State (Cmax,ss)
Not reported.
Time frame: Baseline through Week 100
PK: Area Under the Concentration Versus Time Curve of Tirzepatide for One Dosing Interval at Steady State (AUC(0-ᴛ)ss)
Not reported.
Time frame: Baseline through Week 100
STUDY TEAM
Sponsor and contacts
- Lead sponsor
- Eli Lilly and Company
- Sponsor type
- Industry
- Collaborators
- Not reported
- Organisation study ID
- 27837
Central study contacts
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) orContactPhone: 317-615-4559Email: LillyTrials@Lilly.com
Physicians interested in becoming principal investigators please contactContactEmail: clinical_inquiry_hub@lilly.com
Study officials
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)Study director · Eli Lilly and Company
Contacts are provided by the registry for study enquiries. Do not use these details for marketing or promotions.
FURTHER READING
Results, documents and references
No results are posted in this registry record
This does not mean the study has no findings. Results may not yet have been submitted or published here.
No study documents are listed in this record.